|
|
|
|
|
Valrubicin
drug data and news
Valrubicin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Valrubicin | ||
| Brand Names/Synonyms | AD 32; Antibiotic Ad 32; Valrubicin; Valrubicin [Usan]; Valstar; Valstar Preservative Free | ||
| Indication | Bladder cancer | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | When 800 mg Valstar was administered intravesically to patients with carcinoma in situ, Valstar penetrated into the bladder wall. The mean total anthracycline concentration measured in bladder tissue exceeded the levels causing 90% cytoxicity to human bladder cells cultured in vitro. During the two-hour dose-retention period, the metabolism of Valstar to its major metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol was neglible. After retention, the drug was almost completely excreted by voiding the instillate. Mean percent recovery of Valstar, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samples from six patients was 98.6%, 0.4%, and 99.0% of the total administered drug, respectively. During the two-hour dose-retention period, only nanogram quantities of Valstar were absorbed into the plasma. | ||
| Mechanism Of Action | Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II. | ||
| Valrubicin News (When available) |
| ||
| Dosage Forms | LIQUID | ||
| Drug_Category | Antineoplastic Agents; ATC:L01DB09 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Valrubicin: Because systemic exposure to ValstarÔ is negligible following intravesical administration, the potential for drug interactions is low. No drug interaction studies were conducted. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | [2-oxo-2-[2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-(2,2,2-trifluoroacetyl)amino-tetrahydropyran-2-yl]oxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen-2-yl]-ethyl]pentanoate | ||
| Chemical Formula | C34H36F3NO13 | ||
| Molecular Weight | 723.644 g/mol | ||
| Smiles String | CCCCC(=O)OCC(=O)C1(CC(C2=C(C3=C(C(=C2C1)O)C(=O)C4=C(C3=O)C(=CC=C4)OC)O)OC5CC(C(C(O5)C)O)NC(=O)C(F)(F)F)O | ||
| Melting Point | 116-117°C | ||
| Water Solubility | insoluble | ||
| State | Solid | ||
| LogP/Hphobicity | 3.332 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | >99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Valrubicin.html http://www.rxlist.com/cgi/generic2/rubicin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00662 | ||
| CAS Registry Number | 56124-62-0 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:182424 | ||
| PharmGKB ID | PA451847 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2242466 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |